Skip to content

EYED PHARMA

Active
Public limited companyfounded 201213 yrs activeRue Louis Plescia 9, 4102 Seraing, BelgiumKBO/BCE: BE 0508.599.605
Summary

EYED PHARMA has been active since 2012 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €17.4m and a net result of -€6.9m. Equity is growing by ~18.5% per year across the filed fiscal years. Its solvency ranks better than 34% of 196 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).

Checked score

Score 2025
Axes · tick = 2024
Profitability1▲+1
Solvency59▼-20
Growth35▼-17
Track record100
Bankruptcy probability, 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €950,000 at 30 days acceptable
Liquidity ample (current ratio 2.22 against 1.44 in 2024; short-term debt: 16.1% and cash: 2.6% of total assets), but 65.7% of the assets are financed with debt.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies more bankruptcies →
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
34.3%
Return on assets
-13.7%
Age of the figures
9 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 13 years 0 20 y
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025
Net result per financial year
1819202122232425
2018 to 2025 · latest year -€6.9m
neutral · A punctual record breaks
This company filed 3 consecutive financial years on time. The year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 22-09-2026, 53 days late. Weigh it accordingly: a break into the 1-to-90-day band measures 1.41% abnormal legal state, below the 1.66% market average. It is a change in behaviour, not evidence of elevated risk.
NBB · 10 filings
Deviation from the deadline
2025
53 d late
2024
3 d early
2023
14 d early
2022
33 d early
2021
23 d late
2020
31 d late
2019
31 d late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 13 days after the deadline; the sector median for financial year 2024 is 13 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 28 July (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Position in the running window
30-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

EYED PHARMA was incorporated on 20 December 2012, with a starting capital of EUR 20,000.12 Between 2013 and 2023 the capital was increased 8 times, most recently to EUR 44 million.345 The registered office moved to Liège in 2015 and to Seraing in 2022.67 The board currently has 8 members; RAKIC Jean-Marie Ante has served longest, since 2012.8 Total assets rose from EUR 13 million in 2019 to EUR 51 million in 2025 and headcount from 21.2 to 29 full-time equivalents.9

  1. 1Crossroads Bank for Enterprises
  2. 2Belgian State Gazette, 24-12-2012
  3. 3Belgian State Gazette, 19-12-2013
  4. 4Belgian State Gazette, 27-12-2021
  5. 5Belgian State Gazette, 24-01-2023
  6. 6Belgian State Gazette, 18-05-2015
  7. 7Belgian State Gazette, 23-05-2022
  8. 8Belgian State Gazette, 18-11-2025
  9. 9National Bank, annual accounts 2019 and 2025

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, full schema

Turnover
€10.5m▼ 10.8%
2024 · €11.8m
EBIT margin
-77.8%▼ 7.2pp
2024 · -70.6%
Net result
-€6.9m▲ 0.3%
2024 · -€6.9m
Working capital
€10.0m▲ 145%
2024 · €4.1m
Trend over the years
In euros
In per cent
Ratio
In full-time equivalents (FTE)
In euros
No line ticked in this group.
In per cent
No line ticked in this group.
Ratio
No line ticked in this group.
In full-time equivalents (FTE)
No line ticked in this group.

Untick a line to hide it. Point at a year (or use the arrow keys on the chart) for the exact figures; the table below gives them all.Sector: the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).

Every figure with its change against the fiscal year before
favourable unfavourable
Line20212022202320242025
Turnover€11.8m€10.5m▼ 10.8%
Operating result-€5.1m▼ 85.3%-€7.4m▼ 43.5%-€7.8m▼ 5.3%-€8.3m▼ 7.1%-€8.2m▲ 1.7%
Net result-€4.7mbelow the sector's middle half▼ 84.3%-€6.3mbelow the sector's middle half▼ 34.7%-€6.0mbelow the sector's middle half▲ 4.4%-€6.9mbelow the sector's middle half▼ 15.0%-€6.9mbelow the sector's middle half▲ 0.3%
EBIT margin-70.6%-77.8%▼ 7.2pp
Equity€20.2mabove the sector's middle half▲ 184%€16.3mabove the sector's middle half▼ 19.5%€27.5mabove the sector's middle half▲ 68.9%€22.8mabove the sector's middle half▼ 17.2%€17.4mabove the sector's middle half▼ 23.8%
Total assets€32.7mabove the sector's middle half▲ 109%€27.1mabove the sector's middle half▼ 17.2%€37.9mabove the sector's middle half▲ 39.7%€42.3mabove the sector's middle half▲ 11.8%€50.6mabove the sector's middle half▲ 19.6%
Debt€12.5m▲ 46.7%€10.8m▼ 13.5%€10.3m▼ 4.3%€19.5m▲ 89.0%€33.2m▲ 70.0%
Working capital€13.3mabove the sector's middle half▲ 704%-€362,279below the sector's middle half€8.3mabove the sector's middle half€4.1mabove the sector's middle half▼ 51.0%€10.0mabove the sector's middle half▲ 145%
Solvency61.8%within the sector's middle half▲ 16.2pp60.1%within the sector's middle half▼ 1.7pp72.7%within the sector's middle half▲ 12.6pp53.8%within the sector's middle half▼ 18.9pp34.3%within the sector's middle half▼ 19.5pp
Current ratio3.03within the sector's middle half▲ 1.710.96below the sector's middle half▼ 2.072.44within the sector's middle half▲ 1.481.44within the sector's middle half▼ 0.992.22within the sector's middle half▲ 0.78
Return on assets (ROA)-14.3%below the sector's middle half▲ 1.9pp-23.3%below the sector's middle half▼ 9.0pp-15.9%below the sector's middle half▲ 7.3pp-16.4%within the sector's middle half▼ 0.5pp-13.7%within the sector's middle half▲ 2.7pp
Staff (FTE)32above the sector's middle half▲ 41.6%40above the sector's middle half▲ 25.0%34above the sector's middle half▼ 15.0%33.5above the sector's middle half▼ 1.5%29within the sector's middle half▼ 13.4%
above within below the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings.
Why a figure moved sharply
  • 2023 Equity +69% on 2022. Capital increase of €15,970,358 (Official Gazette 24-01-2023).
  • 2021 Equity +184%, Total assets +109% on 2020. Capital increase of €15,970,358 (Official Gazette 27-12-2021).
Result per fiscal year
Operating resultNet result
-€10.0m-€7.5m-€5.0m-€2.5m€0Operating result 2021: -€5.1m-€5.1mNet result 2021: -€4.7m-€4.7mOperating result 2022: -€7.4m-€7.4mNet result 2022: -€6.3m-€6.3mOperating result 2023: -€7.8m-€7.8mNet result 2023: -€6.0m-€6.0mOperating result 2024: -€8.3m-€8.3mNet result 2024: -€6.9m-€6.9mOperating result 2025: -€8.2m-€8.2mNet result 2025: -€6.9m-€6.9m20212022202320242025-€10m-€7.5m-€5m-€2.5m€0Operating result 2023: -€7.8m-€7.8mNet result 2023: -€6.0m-€6mOperating result 2024: -€8.3m-€8.3mNet result 2024: -€6.9m-€6.9mOperating result 2025: -€8.2m-€8.2mNet result 2025: -€6.9m-€6.9m202320242025
The operating result stays negative: a loss of €8.2m in 2025 against €8.3m in 2024; the loss shrinks.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €50.6m
Fixed assets €32.5m ▲ 11.8%
Current assets €18.1m ▲ 36.6%
Equity and liabilities €50.6m
Equity €17.4m ▼ 23.8%
Debt €33.2m ▲ 70.0%
Debt's share of the balance-sheet total rises from 46.2% to 65.7%. Equity is lower and debt is higher.
Key figures and ratios
2025 value · change against 2024
EBITDA
-€2.7m▲
2024 · -€3.9m
Cash flow
-€1.5m▲
2024 · -€2.5m
Debt to equity
1.91▲
2024 · 0.86
ROE
-39.8%▼
2024 · -30.5%
Interest coverage
-2.06▲
2024 · -10.94
Debt ≤ 1 year
€8.2m▼
2024 · €9.2m
Debt > 1 year
€24.9m▲
2024 · €10.3m
Income taxes
-€245,835▲
2024 · -€324,723
Staff costs
€3.2m▼
2024 · €4.1m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 376 companies that looked in July 2024 the way this one looks now, 0.8% went bankrupt within 24 months and 91% are still going.

  • Small
  • 10 to 20 years old
  • solvency 30% or more
  • a loss of 10% of the balance sheet or more
0.8% went bankrupt
7.2% stopped otherwise
91% still going

A further 0.5% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a bankruptcy probability of 0.3% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,340 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 376 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 54 lines
Balance sheet Code20242025
Assets
Total assets20/58€42.3m€50.6m▲
Fixed assets21/28€29.1m€32.5m▲
Intangible fixed assets21€28.8m€32.2m▲
Tangible fixed assets22/27€309,582€342,244▲
Plant, machinery and equipment23€281,340€319,517▲
Furniture and vehicles24€28,242€22,727▼
Financial fixed assets28€14,550€11,650▼
Current assets29/58€13.3m€18.1m▲
Amounts receivable after more than one year29€1.4m€1.6m▲
Other amounts receivable291€1.4m€1.6m▲
Amounts receivable within one year40/41€8.6m€13.4m▲
Trade receivables40€299,185€314,569▲
Other amounts receivable41€8.3m€13.1m▲
Cash at bank and in hand54/58€1.2m€1.3m▲
Deferred charges and accrued income490/1€2.0m€1.8m▼
Equity and liabilities
Total equity and liabilities10/49€42.3m€50.6m▲
Equity10/15€22.8m€17.4m▼
Contributions10/11€24.8m€24.8m=
Capital10€24.8m€24.8m=
Issued capital100€24.8m€24.8m=
Profit (loss) carried forward14-€13.0m-€19.9m▼
Investment grants15€10.9m€12.4m▲
Amounts payable17/49€19.5m€33.2m▲
Amounts payable after more than one year17€10.3m€24.9m▲
Financial debts170/4€10.3m€24.9m▲
Amounts payable within one year42/48€9.2m€8.2m▼
Current portion of amounts payable after more than one year42€619,642€996,324▲
Financial debts43€5.5m€5.5m=
Credit institutions430/8€5.5m€5.5m=
Trade debts44€2.4m€1.3m▼
Suppliers440/4€2.4m€1.3m▼
Taxes, remuneration and social security45€655,548€347,422▼
Remuneration and social security454/9€655,548€347,422▼
Other amounts payable47/48€528-
Accrued charges and deferred income492/3€8,671€170,794▲
Income statement Code20242025
Turnover70€11.8m€10.5m▼
Goods, raw materials, services and sundry goods60/61€11.5m€10.0m▼
Remuneration, social security and pensions62€4.1m€3.2m▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€4.4m€5.5m▲
Other operating charges640/8€95,165€75,556▼
Gross operating margin9900€254,123€531,035▲
Operating profit (loss)9901-€8.3m-€8.2m▲
Financial income75/76B€1.4m€2.3m▲
Recurring financial income75€1.4m€2.3m▲
Non-recurring financial income76B-€10,465
Financial charges65/66B€356,435€1.3m▲
Recurring financial charges65€356,435€1.3m▲
Profit (loss) for the period before taxes9903-€7.3m-€7.2m▲
Income taxes67/77-€324,723-€245,835▲
Profit (loss) for the period9904-€6.9m-€6.9m▲
Profit (loss) for the period to be appropriated9905-€6.9m-€6.9m▲
Appropriation of the result
Profit (loss) to be appropriated9906-€13.0m-€19.9m▼
Profit (loss) brought forward from the previous period14P-€6.0m-€13.0m▼
Social balance
Average headcount (FTE)908733.529.0▼

The notes to these accounts (19 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20212022202320242025Change
Turnover70---€11.8m€10.5m▼ 10.8%
Goods, raw materials, services and sundry goods60/61---€11.5m€10.0m▼ 13.4%
Remuneration, social security and pensions62€3.0m€4.1m€4.5m€4.1m€3.2m▼ 22.3%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€2.0m€2.8m€4.2m€4.4m€5.5m▲ 24.1%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€0€2,336----
Provisions for liabilities and charges: additions (uses and reversals)635/8---€62,336---
Other operating charges640/8€69,751€20,313€192,126€95,165€75,556▼ 20.6%
Non-recurring operating charges66A€1.4m€1.5m----
Gross operating margin9900€1.3m€1.1m€1.1m€254,123€531,035▲ 109%
Operating profit (loss)9901-€5.1m-€7.4m-€7.8m-€8.3m-€8.2m▲ 1.7%
Financial income75/76B€404,145€964,248€1.6m€1.4m€2.3m▲ 64.9%
Recurring financial income75€404,145€796,562€1.6m€1.4m€2.3m▲ 64.1%
Non-recurring financial income76B-€167,686--€10,465-
Financial charges65/66B€271,423€246,827€199,665€356,435€1.3m▲ 267%
Recurring financial charges65€271,423€246,827€199,665€356,435€1.3m▲ 267%
Profit (loss) for the period before taxes9903-€5.0m-€6.6m-€6.4m-€7.3m-€7.2m▲ 1.4%
Income taxes67/77-€311,542-€334,784-€317,355-€324,723-€245,835▲ 24.3%
Profit (loss) for the period9904-€4.7m-€6.3m-€6.0m-€6.9m-€6.9m▲ 0.3%
Profit (loss) for the period to be appropriated9905-€4.7m-€6.3m-€6.0m-€6.9m-€6.9m▲ 0.3%
Line20212022202320242025Change
Assets
Total assets20/58€32.7m€27.1m€37.9m€42.3m€50.6m▲ 19.6%
Formation expenses20€2,040€1,173€306---
Fixed assets21/28€12.9m€18.9m€23.8m€29.1m€32.5m▲ 11.8%
Intangible fixed assets21€12.3m€18.4m€23.5m€28.8m€32.2m▲ 11.8%
Tangible fixed assets22/27€509,338€478,580€309,574€309,582€342,244▲ 10.6%
Plant, machinery and equipment23€390,265€367,471€255,683€281,340€319,517▲ 13.6%
Furniture and vehicles24€119,073€106,109€53,891€28,242€22,727▼ 19.5%
Assets under construction and advance payments27-€5,000----
Financial fixed assets28€72,354€73,765€34,110€14,550€11,650▼ 19.9%
Current assets29/58€19.8m€8.2m€14.1m€13.3m€18.1m▲ 36.6%
Amounts receivable after more than one year29--€1.1m€1.4m€1.6m▲ 16.0%
Other amounts receivable291--€1.1m€1.4m€1.6m▲ 16.0%
Stocks and contracts in progress3€543,942€454,955€596,833---
Stocks30/36€543,942€454,955€596,833---
Amounts receivable within one year40/41€4.6m€2.5m€10.9m€8.6m€13.4m▲ 55.8%
Trade receivables40€1.3m€1.5m€1.4m€299,185€314,569▲ 5.1%
Other amounts receivable41€3.3m€959,268€9.5m€8.3m€13.1m▲ 57.7%
Cash at bank and in hand54/58€13.5m€3.5m€1.0m€1.2m€1.3m▲ 7.1%
Deferred charges and accrued income490/1€1.2m€1.7m€489,184€2.0m€1.8m▼ 13.2%
Equity and liabilities
Total equity and liabilities10/49€32.7m€27.1m€37.9m€42.3m€50.6m▲ 19.6%
Equity10/15€20.2m€16.3m€27.5m€22.8m€17.4m▼ 23.8%
Contributions10/11€27.9m€27.9m€24.8m€24.8m€24.8m=
Capital10€27.9m€27.9m€24.8m€24.8m€24.8m=
Issued capital100€27.9m€27.9m€24.8m€24.8m€24.8m=
Profit (loss) carried forward14-€12.7m-€19.0m-€6.0m-€13.0m-€19.9m▼ 53.3%
Investment grants15€5.1m€7.4m€8.7m€10.9m€12.4m▲ 13.8%
Amounts payable17/49€12.5m€10.8m€10.3m€19.5m€33.2m▲ 70.0%
Amounts payable after more than one year17€5.9m€2.2m€4.6m€10.3m€24.9m▲ 141%
Financial debts170/4€5.9m€2.2m€4.6m€10.3m€24.9m▲ 141%
Amounts payable within one year42/48€6.5m€8.5m€5.8m€9.2m€8.2m▼ 11.3%
Current portion of amounts payable after more than one year42€857,891€1.5m€1.3m€619,642€996,324▲ 60.8%
Financial debts43€3.5m€1.9m-€5.5m€5.5m=
Credit institutions430/8€3.5m€1.0m-€5.5m€5.5m=
Other loans439-€935,329----
Trade debts44€1.8m€2.1m€3.8m€2.4m€1.3m▼ 45.8%
Suppliers440/4€1.8m€2.1m€3.8m€2.4m€1.3m▼ 45.8%
Taxes, remuneration and social security45€310,597€753,792€676,202€655,548€347,422▼ 47.0%
Taxes450/3€846-----
Remuneration and social security454/9€309,751€753,792€676,202€655,548€347,422▼ 47.0%
Other amounts payable47/48€40,516€2.3m-€528--
Accrued charges and deferred income492/3€41,448€40,378€12,327€8,671€170,794▲ 1,870%
Line20212022202320242025Change
Profit (loss) for the period9904-€4.7m-€6.3m-€6.0m-€6.9m-€6.9m▲ 0.3%
+ Depreciation and write-downs630€2.0m€2.8m€4.2m€4.4m€5.5m▲ 24.1%
Operating cash flow (approximation)-€2.7m-€3.5m-€1.8m-€2.5m-€1.5m▲ 42.7%
Investment in fixed assets (approximation)--€8.8m-€9.1m-€9.7m-€8.9m▲ 8.2%
Change in cash--€10.0m-€2.4m€180,621€86,433▼ 52.1%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
22-09
NBB filing Annual accounts filed
fiscal year 2025 · full schema · 53 days late
2025
18-11
State Gazette act Appointments: Mélanie MESTDAGT, Pierre BELICHARD and 2 others
Resignations: SRL OUKELOS, SA QBIC VENTURE PARTNERS II and Carolyn MYERS · Reappointments: Marc FOIDART, Jean-Marie RAKIC and NOSHAQ SA · Permanent representatives: François MEURGEY, Sofie BAETEN and Eric BRANDT15 facts ▸
  • Board meeting, 20-02-2024
  • Director appointment, Mélanie MESTDAGT (ceo déléguée à la gestion journalière)
  • General meeting, 03-07-2025
  • Director resignation, SRL OUKELOS (independent director)
  • Director resignation, SA QBIC VENTURE PARTNERS II (administrateur de classe c)
  • Director appointment, Pierre BELICHARD (independent director)
  • Director appointment, Robert TAUB (administrateur de classe c)
  • Director resignation, Carolyn MYERS (independent director)
  • Director appointment, Jean-Philippe COMBAL (independent director)
  • Director reappointment, Marc FOIDART (administrateur de classe a)
  • Director reappointment, Jean-Marie RAKIC (administrateur de classe a)
  • Director reappointment, NOSHAQ SA (administrateur de classe b)
  • +3 further facts in this act
28-07
NBB filing Annual accounts filed
fiscal year 2024 · full schema
2024
31-12
Financial Weakest financial yearnet -€6.9m
Net result drops to -€6.9m, the lowest in the series; recovery starts the following year.
17-07
NBB filing Annual accounts filed
fiscal year 2023 · full schema
2023
31-12
Financial Liquidity triplescurrent ratio 2.44
Current ratio from 0.96 to 2.44; short-term debt falls from €8.5m to €5.8m.
31-12
Financial Equity above €25mEq €27.5m ▲68.9%
Equity rises from €16.3m to €27.5m.
23-11
State Gazette act Resignations: REWISE AD REVISEUR D'ENTREPRISES SRL (statutory auditor) and Lawrence VAN HELLEPUTTE (director)
Appointment: BDO EXPERTS COMPTABLES & CONSEILLERS FISCAUX (statutory auditor) · Permanent representative: Bert DE LEEUW · Capital decrease10 facts ▸
  • General meeting, 20-11-2023
  • Capital decrease, €19.033.744
  • Capital, €24.847.913,5
  • Statutes amendment
  • Auditor resignation, REWISE AD REVISEUR D'ENTREPRISES SRL
  • Auditor appointment, BDO EXPERTS COMPTABLES & CONSEILLERS FISCAUX (statutory auditor)
  • Director resignation, Lawrence VAN HELLEPUTTE
  • Permanent representative, Bert DE LEEUW
  • Power of attorney, Manon DEPREZ
  • Power of attorney, Marc FOIDART
28-06
NBB filing Annual accounts filed
fiscal year 2022 · full schema
04-04
State Gazette act Permanent representative: Sofie Baeten
1 fact ▸
  • Permanent representative, Sofie Baeten
24-01
State Gazette act Resignation: PIENTER-JAN (administrateur de classe c)
Appointment: FUND+ (administrateur de classe c) · Permanent representative: Lawrence VAN HELLEPUTTE · Capital increase14 facts ▸
  • General meeting, 20-01-2023
  • Capital increase, €15.970.358
  • Bank account, BE42 0882 8499 1954
  • Capital, €43.881.657,5
  • Share issue, Droits de souscription anti-dilutifs, 110
  • Share issue, Droits de souscription ESOP 2022, 177500
  • Share issue, Droits de souscription ESOP 2023, 177500
  • Statutes amendment
  • Director resignation, PIENTER-JAN (administrateur de classe c)
  • Director discharge, PIENTER-JAN
  • Director appointment, FUND+ (administrateur de classe c)
  • Permanent representative, Lawrence VAN HELLEPUTTE
  • +2 further facts in this act
2022
23-08
NBB filing Annual accounts filed
fiscal year 2021 · full schema · 23 days late
Show earlier events
23-05
State Gazette act Registered office
Registered-office move2 facts ▸
  • Board meeting, 24-03-2022
  • Registered-office move, rue Louis Plescia, 9 à 4102 Seraing (Ougrée)
2021
31-12
Financial Liquidity doublescurrent ratio 3.03
Current ratio from 1.33 to 3.03.
31-12
Financial Equity above €10mEq €20.2m ▲184%
Equity rises from €7.1m to €20.2m.
27-12
State Gazette act Capital & shares · Statutes amendment · Resignations & appointments
Capital increase · Share issue · Capital6 facts ▸
  • General meeting, 20-12-2021
  • Capital increase, €15.970.358
  • Share issue, Droits de souscription anti-dilutifs, 115
  • Share issue, Droits de souscription indemnitaires, 230
  • Capital, €27.911.299,5
  • Statutes amendment
71% of this act was read; anything after the cut is not in this list.Read the act at the Belgisch Staatsblad ↗
31-08
NBB filing Annual accounts filed
fiscal year 2020 · full schema · 31 days late
30-04
State Gazette act Capital & shares · Statutes amendment
Capital increase · Share issue · Capital7 facts ▸
  • Board meeting, 06-04-2021
  • Capital increase, €100.000
  • Share issue, A, 100000
  • Capital, €11.940.941,5
  • Statutes amendment
  • Power of attorney, Anne MICHEL
  • Power of attorney, MESTDAGT Mélanie
2020
31-08
NBB filing Annual accounts filed
fiscal year 2019 · full schema · 31 days late
2019
31-12
Financial Liquidity triplescurrent ratio 4.96
Current ratio from 1.46 to 4.96; short-term debt falls from €2.7m to €1.7m.
31-12
Financial Equity above €5mEq €7.8m ▲190%
Equity rises from €2.7m to €7.8m.
25-11
State Gazette act Permanent representatives: Jean Emile Léon Joseph VAN NUWENBORG and Éric BRANDT
Capital increase · Bank account · Capital11 facts ▸
  • General meeting, 30-09-2019
  • Capital increase, €3.904.732,73
  • Bank account, BE42 0882 8499 1954
  • Capital, €11.840.941,5
  • Share issue, Droits de souscription anti-dilutifs, C
  • Share issue, Droits de souscription ESOP 2019, A
  • Permanent representative, Jean Emile Léon Joseph VAN NUWENBORG
  • Permanent representative, Éric BRANDT
  • Statutes amendment
  • Power of attorney, Mélanie MESTDAGT
  • Subscription rights annulment, Droits de souscription anti-dilutifs, 80
25-11
State Gazette act Capital & shares · Restructuring
Demerger · Accounting effect · Share issue8 facts ▸
  • General meeting, 30-10-2019
  • Demerger, scission partielle par constitution de nouvelle société, ensemble des éléments relatifs à la production d'implants oculaires
  • Accounting effect, 01-07-2019
  • Share issue, 1904688, rémunération de l'apport en nature
  • Capital decrease, €1.306.541,23
  • Capital, €7.936.208,77
  • Statutes amendment
  • Power of attorney, Mélanie MESTDAGT
12-09
State Gazette act Restructuring
Appointment: REWISE AD REVISEUR D'ENTREPRISES SOPRL (réviseur d'entreprises) · Demerger · Capital8 facts ▸
  • Board meeting, 30-08-2019
  • Demerger, transfert de l'ensemble des éléments relatifs à la production d'implants oculaires
  • Capital, €9.242.750
  • Net-asset statement, 30-06-2019
  • Capital, €1.306.541,23
  • Accounting effect, 01-07-2019
  • Auditor appointment, REWISE AD REVISEUR D'ENTREPRISES SOPRL (réviseur d'entreprises)
  • Power of attorney, Raphaël DOUNY
23-07
NBB filing Annual accounts filed
fiscal year 2018 · micro schema
13-06
State Gazette act Resignation: EyeD PHARMA (director)
Appointments: OUKELOS, Marc FOIDART and 5 others · Permanent representatives: François MEURGEY, Chris BUYSE and 2 others · Capital increase21 facts ▸
  • General meeting, 09-05-2019
  • Capital increase, €4.107.750
  • Share issue, warrants anti-dilutifs, 80
  • Statutes amendment
  • Statutes amendment
  • Capital, €9.242.750
  • Director resignation, EyeD PHARMA
  • Director discharge, EyeD PHARMA
  • Director appointment, OUKELOS (independent director)
  • Permanent representative, François MEURGEY
  • Director appointment, Marc FOIDART (class A director)
  • Director appointment, Denis KNOOPS (independent director)
  • +9 further facts in this act
2018
31-08
NBB filing Annual accounts filed
fiscal year 2017 · micro schema · 31 days late
10-07
State Gazette act Appointment: Denis KNOOPS (director)
Capital increase · Bank account · Capital7 facts ▸
  • General meeting, 03-07-2018
  • Capital increase, €2.567.500
  • Bank account, BE42 0882 8499 1954
  • Capital, €5.135.000
  • Statutes amendment
  • Director appointment, Denis KNOOPS (director)
  • Power of attorney, Mélanie MESTDAGT
2017
29-09
NBB filing Annual accounts filed
fiscal year 2016 · micro schema · 60 days late
2016
13-12
State Gazette act Appointments: Société d'Investissement et de Participation du Bassin de Liège, Henri Lemaître and 3 others
Permanent representatives: Françoise Leblanc and Marc Foidart · Reappointments: Marc Foidart, Biofinance Consulting and Jean-Marie Rakic · Resignations: OUSIA (director) and Christine Jérôme (director)13 facts ▸
  • General meeting, 30-06-2016
  • Director appointment, Société d'Investissement et de Participation du Bassin de Liège (director)
  • Permanent representative, Françoise Leblanc
  • Director appointment, Henri Lemaître (director)
  • Director appointment, Jean-Michel Foidart (director)
  • Director appointment, Mercury Leadership and Management (director)
  • Director reappointment, Marc Foidart (director)
  • Director reappointment, Biofinance Consulting (managing director)
  • Director reappointment, Jean-Marie Rakic (président du conseil d'adm.)
  • Director resignation, OUSIA (director)
  • Permanent representative, Marc Foidart
  • Director resignation, Christine Jérôme (director)
  • +1 further facts in this act
08-07
State Gazette act Capital & shares · Statutes amendment
Capital increase · Bank account · Capital8 facts ▸
  • General meeting, 22-06-2016
  • Capital increase, €1.967.500
  • Bank account, BE89 0882 7497 4985
  • Capital, €2.567.500
  • Statutes amendment
  • Power of attorney, Mélanie MESTDAGT
  • Share categories, 893500, 100000
  • Power of attorney, Françoise LEBLANC
06-05
State Gazette act Capital & shares
Share issue · Power of attorney · Warrant exercise period6 facts ▸
  • General meeting, 14-04-2016
  • Share issue, 100000, warrants
  • Power of attorney, Mélanie MESTDAGT
  • Warrant exercise period, 14-04-2021, 01-01-2020
  • Warrant transferability, registre de Détenteurs de Warrants au siège social
  • Share form, nominative
02-05
State Gazette act Appointment: Marc Foidart (director)
Resignation: Majocepi (director)3 facts ▸
  • General meeting, 01-02-2016
  • Director appointment, Marc Foidart (director)
  • Director resignation, Majocepi (director)
2015
18-05
State Gazette act Registered office
Registered-office move2 facts ▸
  • General meeting, 06-05-2015
  • Registered-office move, Quartier Hôpital, Avenue Hippocrate 5, 4000 Liège
2013
19-12
State Gazette act Appointments: Jean-Marie RAKIC, BIOFINANCE CONSULTING and 3 others
Permanent representatives: Mélanie MESTDAGT, Jean-Michel FOIDART and Marc FOIDART · Capital increase · Bank account16 facts ▸
  • General meeting, 30-10-2013
  • Capital increase, €580.000
  • Bank account, Banque AXA, BE12 7512 0617 8792
  • Legal-form conversion, Société Anonyme
  • Net-asset statement, 30-09-2013
  • Capital, €600.000
  • Director appointment, Jean-Marie RAKIC (chair)
  • Director appointment, BIOFINANCE CONSULTING (managing director)
  • Permanent representative, Mélanie MESTDAGT
  • Director appointment, MAJOCEPI (director)
  • Permanent representative, Jean-Michel FOIDART
  • Director appointment, OUSIA (director)
  • +4 further facts in this act
2012
24-12
State Gazette act Incorporation
Appointment: RAKIC Jean-Marie Ante (non-statutory manager) · Founding capital · Power of attorney7 facts ▸
  • Incorporation, 14-12-2012
  • Founding capital, €20.000
  • Director appointment, RAKIC Jean-Marie Ante (non-statutory manager)
  • Power of attorney, RAKIC Jean-Marie Ante
  • Power of attorney, RAKIC Jean-Marie Ante
  • Power of attorney, RAKIC Jean-Marie Ante
  • Assumption of prior commitments, Le gérant reprend les engagements, ainsi que les obligations qui en résultent, et toutes les activités entreprises depuis le 1er février 2012 par ses soins au n…
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
19 of 20 acts read
About the unread acts

Of the 20 Belgian State Gazette acts we know for this company, 19 have been read. The other one has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
7 directors, 1 in day-to-day management, last change in 2025

Board 7

RAKIC Jean-Marie Ante
Président du conseil d'adm. · since 30-10-2013 · Administrateur de classe a · since 20-12-2012
Current
FOIDART Marc
Administrateur de classe a · since 01-02-2016
Current
Fund+
Administrateur de classe c · since 20-01-2023 · Public limited company · perm. rep.: Lawrence VAN HELLEPUTTE
Current
Robert TAUB
Administrateur de classe c · since 15-12-2024
Current
Pierre BELICHARD
Independent director · since 23-04-2025
Current
Jean-Philippe COMBAL
Independent director · since 03-07-2025
Current
NOSHAQ SA
Administrateur de classe b · since 03-07-2025 · Legal entity · perm. rep.: Eric BRANDT
Current
9 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
FOIDART Jean-Michel
Director · since 30-06-2016
Not recently confirmed
Henri LEMAITRE
Director · since 30-06-2016
Not recently confirmed
Mercury Leadership and Management
Director · since 30-06-2016 · Legal entity
Not recently confirmed
Oukelos
Director · since 30-06-2016 · Legal entity
Not recently confirmed
Société d'Investissement et de Participation du Bassin de Liège
Director · since 30-06-2016 · Legal entity · perm. rep.: Françoise Leblanc
Not recently confirmed
KNOOPS Denis
Independent director · since 03-07-2018
Not recently confirmed
MEUSINVEST
Class B director · since 09-05-2019 · Legal entity · perm. rep.: Françoise LEBLANC
Not recently confirmed
OUKELOS
Independent director · since 09-05-2019 · Private limited company · perm. rep.: François MEURGEY
Not recently confirmed
Qbic Venture Partners II
Class B director · since 09-05-2019 · Legal entity
Not recently confirmed

Day-to-day management 1

Mélanie MESTDAGT
Ceo déléguée à la gestion journalière · since 01-03-2024
Current
1 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
BIOFINANCE CONSULTING
Managing director · since 30-10-2013 · Legal entity · perm. rep.: Mélanie MESTDAGT
Not recently confirmed

Permanent representatives 2

Lawrence VAN HELLEPUTTE
Permanent representative · since 20-01-2023 · for Fund+
Current
Eric BRANDT
Permanent representative · since 03-07-2025 · for NOSHAQ SA
Current
3 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
Mélanie MESTDAGT
Permanent representative · since 30-10-2013 · for BIOFINANCE CONSULTING
Not recently confirmed
François MEURGEY
Permanent representative · since 09-05-2019 · for OUKELOS
Not recently confirmed
Françoise LEBLANC
Permanent representative · since 09-05-2019 · for MEUSINVEST
Not recently confirmed

Statutory auditor 1

BDO EXPERTS COMPTABLES & CONSEILLERS FISCAUX
Statutory auditor · since 20-11-2023 · perm. rep.: Cédric ANTONELLI
Current
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ. See the function holders in the CBE →
Not every act has been read: a resignation may be missing here
1 of this company's 20 Belgian State Gazette acts has not been read yet. 1 act was read only in part. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Seraing · 1 establishment unit since 2012
seat establishment approximate The establishment unit on the map
Ground area
8,627 m²
Parcel 62343C0011/00N005, Wallonia. Linked by address, not a title deed.
1 establishment unit
Rue Louis Plescia 9, 4102 Seraing
Retail trade
since 20122.218.862.726
1 parcel
Wallonia 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
62343C0011/00N005 Wallonia 8,627 m² - -
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Mandate history

26 people since 2012, 19 in office
Show
  • Board
  • Day-to-day management
  • Statutory auditor
  • not recently confirmed
  • began earlier
Mandates per person, with start and end dates
Name Functions and periods
RAKIC Jean-Marie Ante
  • Non-statutory manager, from 20-12-2012 to date
  • Chair, from 30-10-2013 not ended, last confirmed 13-12-2016
FOIDART Marc
  • Director, from 01-02-2016 to date
Fund+
  • Administrateur de classe c, from 20-01-2023 to date
Robert TAUB
  • Administrateur de classe c, from 15-12-2024 to date
Pierre BELICHARD
  • Independent director, from 23-04-2025 to date
Jean-Philippe COMBAL
  • Independent director, from 03-07-2025 to date
NOSHAQ SA
  • Administrateur de classe b, already before 03-07-2025 to date
Mélanie MESTDAGT
  • Ceo déléguée à la gestion journalière, from 01-03-2024 to date
BDO EXPERTS COMPTABLES & CONSEILLERS FISCAUX
  • Statutory auditor, from 20-11-2023 to date
FOIDART Jean-Michel
  • Director, from 30-06-2016 not ended, last confirmed 13-12-2016
Henri LEMAITRE
  • Director, from 30-06-2016 not ended, last confirmed 13-12-2016
Mercury Leadership and Management
  • Director, from 30-06-2016 not ended, last confirmed 13-12-2016
Oukelos
  • Director, from 30-06-2016 not ended, last confirmed 13-12-2016
Société d'Investissement et de Participation du Bassin de Liège
  • Director, from 30-06-2016 not ended, last confirmed 13-12-2016
KNOOPS Denis
  • Director, from 03-07-2018 not ended, last confirmed 13-06-2019
MEUSINVEST
  • Class B director, from 09-05-2019 not ended, last confirmed 13-06-2019
OUKELOS
  • Independent director, from 09-05-2019 not ended, last confirmed 13-06-2019
Qbic Venture Partners II
  • Class B director, from 09-05-2019 not ended, last confirmed 13-06-2019
BIOFINANCE CONSULTING
  • Managing director, from 30-10-2013 not ended, last confirmed 13-12-2016
Carolyn MYERS
  • Independent director, until 24-06-2025
SRL OUKELOS
  • Independent director, until 22-04-2025
SA QBIC VENTURE PARTNERS II
  • Administrateur de classe c, until 15-12-2024
REWISE AD REVISEUR D'ENTREPRISES SOPRL
  • Réviseur d'entreprises, from 02-09-2019 to 20-11-2023
Christine Jérôme
  • Director, from 30-10-2013 to 30-06-2016
OUSIA
  • Director, from 30-10-2013 to 30-06-2016
MAJOCEPI
  • Director, from 30-10-2013 to 01-02-2016
See the board, name and seat on a given date →

Articles of association

Purpose
Le développement, la production et la commercialisation de médicaments sous les formes les plus diverses, d'implants médicaux à visée thérapeutique, de formulations galéniques, et…
Full purpose

Le développement, la production et la commercialisation de médicaments sous les formes les plus diverses, d'implants médicaux à visée thérapeutique, de formulations galéniques, et notamment dans le domaine ophtalmologique ; L'achat, la détention, la vente, la cession, l'échange, la gestion de toute valeur mobilière, action, obligation ou titre de prêt émis par toutes sociétés belge ou étrangère, part sociale ou autres droits sociétaires ; La prise de participation sous quelque forme que ce soit dans des sociétés industrielles, commerciales, financières, existantes ou à constituer ; La réalisation de toutes opérations financières à l'exception de celles réservées par la loi aux banques et caisses d'épargne et de celles visées par l'arrêté royal du cinq août 1991 relatif à la gestion de fortune et au conseil de placements. La réalisation de toute opération à caractère immobilier, telle que l'achat, la détention, la vente, la cession, l'échange, la construction, la gestion de toutes propriétés immobilières, bâties ou non bâties, qu'elle peut également donner en location en ce compris la location-financement ; L'exercice et l'application de tous droits et pouvoirs conférés par ou attachés à la propriété de toute action, valeur mobilière ou autres titres comprenant et ceci sans préjudice de ce qui précède, tous pouvoirs de veto ou de contrôle conféré en vertu de la participation par la société d'une partie ou d'une quotité spéciale du capital souscrit et pourvoir des services de management et autres services de direction, de supervision ou de conseil pour ou en relation avec toute société dans laquelle la société est intéressée, aux conditions qu'elle jugera bonnes ; L'exercice des fonctions de mandataire sous toutes formes, de gérant, d'administrateur et/ou de liquidateur dans d'autres sociétés, participées ou non, en Belgique et à l'étranger ; La réalisation de toutes prestations de conseil, d'expertise et de formation pour toutes entreprises et sociétés de services notamment dans les domaines de l'administration, marketing, du management, de la stratégie d'entreprise, de la finance, des mathématiques, de l'informatique et de l'économie, ce dans le sens le plus large du terme ; Le développement, l'achat, la vente, la gestion, la mise en valeur, la prise ou l'attribution de licences, de brevets, de know-how, et autres droits intellectuels ; La gestion, dans la plus large acception du terme, de son patrimoine immobilier propre.

Structure & network

Owners and holdings

4 owners

According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.

Connections & network

23 connected companies
Linked via shared directors
NOSHAQ PARTNERS
via FOIDART Marc · Permanent representative
→
BIO-SOURCING
via FOIDART Marc · Permanent representative
former→
GESVAL
via FOIDART Marc · Director
former→
Hyloris Pharmaceuticals
via FOIDART Marc · Independent director
former→
Show 19 more companies with a shared director
MAN & SCIENCE
via FOIDART Marc · Permanent representative
former→
NOSHAQ
via FOIDART Marc · Permanent representative
former→
NOSHAQ VENTURE
via FOIDART Marc · Permanent representative
former→
OUSIA OPERATIONS
via FOIDART Marc · Permanent representative
former→
former→
CALI EVOLUTION
Shared director
→
→
NOSHAQ ENERGY
Shared director
→
NOSHAQ EUROPE 3
Shared director
→
NOSHAQ IMMO
Shared director
→
NOSHAQ SPIN-OFFS
Shared director
→
The Shift
Shared director
→
Aelin Therapeutics
Shared corporate director
→

Acquisitions and mergers

1 transaction
Split off to:UniD Manufacturing
partial demerger · State Gazette act of 25-11-2019 (2 acts)

Capital and shareholders

Shareholders according to the acts
After the capital increase act of 30-04-2021 ↗
After the capital increase act of 13-06-2019 ↗
After the capital increase act of 10-07-2018 ↗
  • Jean-Marie RAKIC 42,494 shares · 254,966.35 EUR
  • Yvette POUTCHINIAN 3,333 shares · 20,000 EUR
  • Agnès NOEL 3,993 shares · 23,956 EUR
  • OUSIA 8,603 shares · 51,618.14 EUR
  • Marc FOIDART 62,473 shares · 374,835.86 EUR
  • John FOIDART 24,654 shares · 147,923 EUR
  • Pierre FOIDART 24,654 shares · 147,923 EUR
  • Céline FOIDART 24,654 shares · 147,923 EUR
  • OPHTALMOS 81,144 shares · 486,866.17 EUR
  • MEUSINVEST 83,333 shares · 499,998 EUR
  • Henri LEMAÎTRE 17,956 shares · 107,735.29 EUR
  • André MALHERBE 17,956 shares · 107,735.29 EUR
  • Fabienne WIJZEN 2,868 shares · 17,208.48 EUR
  • Mélanie MESTDAGT 2,868 shares · 17,208.48 EUR
  • Philippe Jean-Marie Léopold DEGEER 26,934 shares · 161,602.94 EUR
After the capital increase act of 08-07-2016 ↗
After the capital increase act of 19-12-2013 ↗
  • RAKIC Jean-Marie 64,438 EUR
  • POUTCHINIAN Yvette 96,657 EUR
  • DUCHATEAU Edouard 64,438 EUR
  • NOEL Agnès 32,219 EUR
  • MAJOCEPI SPRL 257,810 EUR
  • Ousia SPRL 64,438 EUR

The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years
  1. 23-11-2023 Capital reduction of 19,033,744 EUR · to 24,847,913.50 EUR · to absorb losses
  2. 24-01-2023 Capital increase of 15,970,358 EUR · to 43,881,657.50 EUR · 1,581,046 new shares
  3. 27-12-2021 Capital increase of 15,970,358 EUR · to 27,911,299.50 EUR · 1,581,046 new shares
  4. 30-04-2021 Capital increase of 100,000 EUR · to 11,940,941.50 EUR
  5. 25-11-2019 Capital reduction of 1,306,541.23 EUR · to 7,936,208.77 EUR
  6. 25-11-2019 Capital increase of 3,904,732.73 EUR · to 11,840,941.50 EUR · 483,259 new shares
  7. 12-09-2019 Capital stated in the act · 9,242,750 EUR · 1,904,688 shares
  8. 13-06-2019 Capital increase of 4,107,750 EUR · to 9,242,750 EUR · 483,271 new shares
Show 4 older capital entries
  1. 10-07-2018 Capital increase of 2,567,500 EUR · to 5,135,000 EUR · 427,917 new shares
  2. 08-07-2016 Capital increase of 1,967,500 EUR · to 2,567,500 EUR · 393,500 new shares
  3. 19-12-2013 Capital increase of 580,000 EUR · to 600,000 EUR
  4. 24-12-2012 Incorporation · 20,000 EUR · 20,000 shares

Similar companies · same sector, comparable size

Of 762 companies in sector 72101 we hold annual accounts for 484. 112 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPublic limited company
Founded20-12-2012
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
E-invoicing
Reachable via Peppol
Peppol ID 0208:0508599605
Also 9925:BE0508599605
Registered 28-08-2025

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 30 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.